Back

Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 7 - Lipids Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Antonio J Vallejo-Vaz

University of Seville, Seville (Spain)

14 More presentations in this session

Presentation thumbnail
Impact of the european and american guidelines on the management and treatment of dyslipidemia in a spanish working population
Doctor C. Brotons (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Management of hypercholesterolaemia in non-Western countries and achievement of LDL-C goals: an international, cross-sectional, observational study
Professor N. Danchin (Paris, FR)
Abstract Slides
Presentation thumbnail
Lipid goals are poorly attained in majority of patients with familial hypercholesterolemia in Latvia at the time of inclusion in the national registry
Professor G. Latkovskis (Riga, LV)
Abstract Slides
Presentation thumbnail
The metabolism of triglyceride-rich lipoproteins is impaired in patients with obstructive sleep apnoea: effects of treatment with continuous positive airway pressure.
Associate Professor L. Drager (Sao Paulo, BR)
Abstract
Presentation thumbnail
Clinical characteristics and cardiovascular outcomes in subjects who developed acute myocardial infarction despite statin therapy.
Doctor K. Tsuda (Takatsuki, JP)
Abstract

Access the full session

Session thumbnail
Poster session 7 - Lipids

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources